Journal
CYTOTHERAPY
Volume 12, Issue 8, Pages 1044-1055Publisher
ELSEVIER SCI LTD
DOI: 10.3109/14653249.2010.504770
Keywords
adoptive immunotherapy; ex vivo expansion; good manufacturing practice; natural killer cells; NKp44
Categories
Funding
- Swedish Research Council
- Swedish Children's Cancer Foundation
- Avaris AB
- European Union [LSHB-CT-2006-018933]
- Scientific and Technological Research Council of Turkey [2213]
Ask authors/readers for more resources
Background aims. Natural killer (NK) cell-based adoptive immunotherapy is a promising approach for the treatment of cancer. Ex vivo expansion and activation of NK cells under good manufacturing practice (GMP) conditions are crucial for facilitating large clinical trials. The goal of this study was to optimize a large-scale, feeder-free, closed system for efficient NK cell expansion. Methods. Peripheral blood mononuclear cells (PBMCs) from healthy donors and myeloma patients were cultured for 21 days using flasks, cell culture bags and bioreactors. Final products from different expansions were evaluated comparatively for phenotype and functionality. Results. Significant NK cell expansions were obtained in all systems. The bioreactor yielded a final product rich in NK cells (mean 38%) ensuring that a clinically relevant cell dose was reached (mean 9.8 x 10
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available